Chemotherapy Induced Peripheral Neuropathy (CIPN): Cellular and Molecular Mechanisms of Chemotherapy Induced Peripheral Neuropathy Pathophysiology
15m 59s
Chemotherapy-induced peripheral neuropathy (CIPN) remains a complex and poorly understood condition despite decades of research. While neuroinflammation, mitochondrial dysfunction, and axonal transport deficits are recognized contributors, no single mechanism fully explains CIPN pathogenesis. Different chemotherapies—such as oxaliplatin—trigger distinct molecular pathways, implying that CIPN may vary by agent. Although early strategies like antioxidants failed, emerging targets such as the SARM1 pathway and HDAC6 offer promising, neuron-specific therapeutic avenues. A critical limitation in research is the reliance on animal models that prioritize pain induction over actual axonal degeneration, reducing clinical relevance. To improve translation, models must better replicate human dosing, administration routes, and the full spectrum of neurological impairment. Current evidence suggests that targeting shared final pathways of axonal degeneration may yield broad therapeutic benefits across CIPN and other neuropathies. Preclinical studies on SARM1 and HDAC6 inhibition show encouraging results, indicating potential for near-future clinical trials. Success will depend on refining models to reflect real-world clinical conditions and advancing targeted, neuroprotective therapies that do not compromise anticancer efficacy.
(upbeat music)
Welcome to the Peripheral Nerd Podcast,
the official podcast of the Peripheral Nerd Society.
Exploring topics in Peripheral Nerd disorders,
a warmness, education, and advocacy.
We are your author, Dr. Paolo Berti
from University of Milano Bicocca, Italy.
And professors is an apart
from the University of Sydney, Australia.
We're delighted to bring you a new series
of the Peripheral Nerd Podcast,
entitled Understanding Chemotherapy and Juice
Peripheral Neuropathy, or CIPN.
The goal of this series is to explore CIPN
through different lenses, including oncology,
neurology, basic science, as well as patient experience.
Each month will dissect a different aspect of CIPN
by lighting pathophysiology, risk factors,
and emerging biomarkers, with the aim
of explaining the spectrum of CIPN research
from basic science to clinical translation.
In this episode, we will discuss cellular
and molecular mechanism of CIPN pathophysiology.
We are honoured to welcome Professor Widu Cavaletti.
Professor Cavaletti is one of the global leaders
in the field of CIPN research.
The decades Professor Cavaletti has led the way
in understanding how cancer treatments
affect the Peripheral Nerd system.
This work has had a really substantial impact,
both in the clinical setting,
through defining key assessment tools
for the identification and monitoring of CIPN,
and through advances in pre-clinical models
to help us identify key mechanisms of CIPN.
- Why can't Professor Cavaletti?
It's a true honour to have you here with us today.
- Thank you for your invitation to join you
and this podcast.
- Yes, if we could start,
if you could give us an overview
of the key mechanisms known today
about the cellular and molecular mechanisms driving CIPN.
- Well, this is a very good question
because I started working on CIPN in the early nineties,
and it's sad to say that we don't know exactly
which is the mechanism of CIPN,
despite intensive effort over the years.
At the moment, one of the most relevant aspects of CIPN
seems to be related to what it's called the newer inflammation.
So the response of the organism to the toxic injury
that might allow the development of a sort of wrong response
driven by inflammation acting on the peripheral nervous system.
- Do you think that other aspects,
such as external transport deficits,
also contribute to those?
- Yeah, it is very clear that it's a key point.
What is not clear is whether this is the starting of the event
or only the end of the story, once neurons and axons are damaged,
but for sure, some of the drugs can act directly
on the market tubal,
and so it's very likely that the external transport
can be impaired.
- In line with that, I was wondering, since key drugs
do have different mechanism of action against cancer,
to what extent are the cellular and molecular mechanism
dragging CIPN potentially different among those several
anticharcent drug targeting the PNS,
which is your insight?
- Well, we have some very precise idea regarding
some specific mechanisms.
For instance, those are the basis of the acute neurotoxicity
of oxaliplatin.
In that case, there is a clear interference
with the activity of the ion channels.
And it is reasonable that the different drugs
can have different mechanisms at the basis of the final event
that in all the cases is the same.
Unfortunately, it's axonopathy,
and this is not helping us in understanding
which are the starting events.
Anyway, what is the very clear point
is that we should be very carefully interpreting
the mechanism of the anti-cancer activity of the drugs
as the same mechanism in charge of developing neurotoxicity,
because we are dealing with completely different kind of cells,
and the same mechanism cannot work in the same way
for a cancer cell and for neuron.
- And do you think that these could potentially mean
that if I want to find a cure for CIPN,
it might be slightly different,
depending on the chemo drug I'm gonna administer?
- Yes, this is a theory.
If we will be able to re-understand
which are the specific mechanisms at the basis
of the neurotoxicity of each of the drugs
would be much easier to target with the drug that mechanism.
At the moment, we are not at that point, unfortunately.
I remember since I'm quite old
that at the very beginning of the story,
the antioxidant drugs were very promising
because there was the idea that the impairment
in mitochondrial function was the main event
with most of the drugs leading to oxidative stress.
Unfortunately, all the attempts with the antioxidant failed,
and in some cases, there was also some concern
about the safety of the combination
of these antioxidant drugs with the anticancer agents.
So the answer to your question is difficult
if we consider the theory
and what we really know at this moment.
- Thank you.
Thanks so much, Guido.
I think I would also like to ask you
about the commonality of these mechanisms
that we've identified as being involved in CIPN
and how translatable these might be
to other forms of peripheral neuropathy
or axon degeneration in general.
- If we look at the final event,
independently from the drug we are considering,
what we see in our patient
that also in the animal models is a loss in axons.
This is a fairly common event
in several kinds of different neuropathies.
So the final electron degeneration is very likely
to be driven by common mechanisms.
This is the reason why, in some cases,
we should think of targeting that final event
and not considering which is the beginning of the story.
But of course, this is a fairly rough approach,
although at the moment seems to be probably
the most promising of owning the short term.
- Do you think that some of these mechanisms
can also be applied to central nervous system
near degenerative conditions
or do you think that this is more specific
to the peripheral nervous system?
- Another very good question.
I will try to answer, although I'm not sure
about the real situation.
What we know with that, the same anti-cancer drugs
can also induce central nervous system impairment,
despite the fact that they are completely
or nearly completely unable to cross
the intact blood brain barrier.
So it's very difficult to imagine a direct interaction
with the central nervous system neurons.
However, since we have, in any case,
a central nervous system impairment,
what is called chemo fog or chemo brain,
some event induced by the delivery of the drug
should be able to produce all the central nervous system damage.
If the mechanism is the same
of the peripheral nervous system damage,
it's really an open question.
At the moment, my personal feeling is that
the mechanism is not the same,
but it's not so easy to understand
if it's through or not my statement,
mostly because in patients it's very difficult
to investigate the topic.
And the animal bothers of the central nervous system
impairment due to chemo therapy
are not easily available.
And they do not really reproduce the human situation.
- Great, thank you.
- Ah, thank you so much for this link.
It just made me a reason on another
of the great advancement that you provided
with your decades of research.
The translitability of clinical models,
I was wondering, as you were mentioning,
that some times the models are not ideal
in reproducing the human condition
and what are your insights, your,
let's say, suggestions when you would like to go
or let's say your model that will ensure an effected
translation from bench to bed size and vice versa.
- Unfortunately, not only in the field of CIPN,
but in general, we are well aware of several failer
in the translation of the animal models results
into the clinical situation.
Specifically, regardless of CIPN,
translation should not be so difficult,
at least again, in theory, because the cause
of the neuropathy is clear.
So it's the administration of the neurotoxic agent.
The target is quite evident.
And we have several ways to be very close
to the human condition in our animal models.
Unfortunately, I think that we have a fundamental bias
in the use of the animal models,
that is represented by the fact that in several cases,
CIPN can induce neuropatic pain.
And these tend to apply pain-driven approach
to the use of animal models.
I mean that most of the animal models of CIPN
actually are animal models of neuropatic pain
induced by chemotherapy drugs.
And in my view, this is not exactly the same,
just to make an example.
inducing neuropatic pain without an over-damage of the peripheral nerves is
something that is very far from the clinical condition of the patients where a neuropathic
pain is always coupled with an impairment also in the functioning of the nerves and that
this is very clear not only by the neurological assessment but also by the neurophysiological
investigations.
And I was wondering when you check literature and you compare pro-clinical borders, a few
things are quite evident.
First of all, shadow, you compare different papers on different groups and the shadow
is not the same but we know that CIPN does depend on events so I was wondering which is
your insight you could provide on this aspect.
There are some, let's say, minimum levels we should reach and if you could suggest some
outcome measure to ensure that our model is strong enough to say your appetite is there
and not just, as you were saying, a painful manifestation.
Well, I will start from the end.
If I have a model where I am unable to see axonopathy so if you are unable to demonstrate
that in the peripheral nerves we are losing fibers.
I very, very concerned about considering that model has represented you in the human situation.
My key point is schedule is something that should be very carefully considered, not only
in terms of doses but also in terms of timing.
Patients are not exposed to repeated injections every other day.
They are generally exposed to the drug with an interval between the administrations.
And if I am using a model where I inject the animals every day or every other day, I
can do something that is really very far from the clinical condition.
So in my view, all the clinical behavior that can be very produced into the model should
be used.
So if the drug is given intravenously inpatient, I prefer giving the drug intravenously
also in the animals.
If I need a readout that can be easily translated from the animal model as to the patient, I would
use neurophysiology or scimbalsy at most.
My point is start from the clinical condition and go back to the model in order to try to
make a copy as far as possible of the human and clinical condition.
Thank you.
You're very helpful.
Thank you, Guido.
I guess based on your experience over these decades, what do you think now is the most
promising avenue for future research?
The most promising strategy at the moment.
As far as I know, one of the lines that are currently under investigation and they've
very good biological, rational, is the use of drugs able to target the Sarmuan pathway.
Sarmuan is a molecule that is really a key player in axonal degeneration, not only in
CIPN, but also in other kinds of axonal degeneration.
But it's very specific for neurons using inhibitors of Sarmuan might be helpful both to prevent
axonal damage and also to avoid any reasonable interference with the activity of the anti-cancer
drugs.
It should be tested, of course, but the biological background is suggesting that it's a safe approach.
Another potentially useful strategy that it's based on the evidence that the acetylation
of the microcubulin is an important event during some kind of a sonal degeneration, including
genetic neuropathies, is targeting H-DAC-6, so it's done the acetylase-6.
That is specific for neurons can be targeted by a small molecule and animal models have shown
promising results against the degeneration in different models, both genetic neuropathies
and also at least with dynchristine in animal models.
So these two seems to be at the moment, in my view, the most promising and the most advanced
attempt to tackle CIPN.
Thank you so much, and that's really interesting.
I guess in terms of the next steps for this field of research, are there other models you
think these drugs should be tested in or do you think that we're getting ready for human
translation in the next five to ten years?
I hope that we'll be able to go into the technical testing in the next few years.
The safety profile of both these family of drugs is fairly good.
The bioballability is also promising, so probably in the near future we will see some
attempts to go into the clinical, into the clinical testing.
At least this is my open.
Fantastic.
Thank you so much, Professor Cavaletti, for sharing your insights about this important
field of research.
That's all we have time for.
You can find relevant papers in the show notes and you can visit www.pnssociety.com for
more information about the peripheral nerve society.
Thank you so much for listening and see you next month.
The primary purpose of the peripheral nerve podcast is to meet the educational needs of
its listeners and address practice gaps by providing practice oriented and scientifically
based education that will maintain an advanced competence and performance in the peripheral
nerve field.
A diversity of opinions exists in the medical field and the views of the podcast faculty
do not represent those of the peripheral nerve society or constitute an endorsement by
the peripheral nerve society.
Podcast Summary
Key Points:
The cellular and molecular mechanisms of chemotherapy-induced peripheral neuropathy (CIPN) remain incompletely understood, with neuroinflammation currently considered a central component.
Drug-induced disruptions in axonal transport and mitochondrial dysfunction are key contributors, though whether these initiate or follow neuronal damage is still debated.
Different chemotherapeutic agents exhibit distinct mechanisms—such as oxaliplatin’s interference with ion channels—suggesting potential variability in CIPN development.
While antioxidant strategies were once promising, they have failed clinically, highlighting the complexity of targeting oxidative stress in CIPN.
Axonal degeneration is a common endpoint in CIPN and other peripheral neuropathies, suggesting shared final pathways that could be therapeutically targeted.
Current animal models often focus on pain-related outcomes rather than full axonal loss, limiting translational relevance to human disease.
Targeting the SARM1 pathway and histone deacetylase 6 (HDAC6) shows strong preclinical promise for preventing axonal damage without interfering with anticancer efficacy.
Future research should prioritize models that closely mimic human dosing, delivery routes, and clinical symptoms to improve translational validity.
Summary:
Chemotherapy-induced peripheral neuropathy (CIPN) remains a complex and poorly understood condition despite decades of research. While neuroinflammation, mitochondrial dysfunction, and axonal transport deficits are recognized contributors, no single mechanism fully explains CIPN pathogenesis. Different chemotherapies—such as oxaliplatin—trigger distinct molecular pathways, implying that CIPN may vary by agent.
Although early strategies like antioxidants failed, emerging targets such as the SARM1 pathway and HDAC6 offer promising, neuron-specific therapeutic avenues. A critical limitation in research is the reliance on animal models that prioritize pain induction over actual axonal degeneration, reducing clinical relevance. To improve translation, models must better replicate human dosing, administration routes, and the full spectrum of neurological impairment.
Current evidence suggests that targeting shared final pathways of axonal degeneration may yield broad therapeutic benefits across CIPN and other neuropathies. Preclinical studies on SARM1 and HDAC6 inhibition show encouraging results, indicating potential for near-future clinical trials. Success will depend on refining models to reflect real-world clinical conditions and advancing targeted, neuroprotective therapies that do not compromise anticancer efficacy.
FAQs
The primary mechanism involves neuroinflammation triggered by toxic injury to the peripheral nervous system. Oxidative stress and impaired axonal transport are also involved, though the exact initiating events remain unclear.
While some drugs like oxaliplatin directly interfere with ion channels, the overall outcome—axonopathy—is similar. However, the specific mechanisms may vary, suggesting that treatment approaches could differ based on the drug used.
Yes, the final event—axon loss—is common across various neuropathies. Targeting this shared endpoint may offer broad therapeutic benefits, even if the initial triggers differ.
While drugs typically don’t cross the blood-brain barrier, central nervous system effects like 'chemo fog' may result from indirect mechanisms. Whether the underlying pathophysiology is identical remains uncertain.
Antioxidants were initially promising due to the theory of mitochondrial oxidative stress, but clinical trials failed. Concerns about safety and interactions with anticancer drugs also limited their effectiveness.
Models should more closely mimic human conditions, including proper dosing schedules, drug administration routes, and neurophysiological assessments. Avoiding pain-focused models that don’t reflect real axon damage is critical.
Chat with AI
Loading...
Pro features
Go deeper with this episode
Unlock creator-grade tools that turn any transcript into show notes and subtitle files.